23andMe, the DNA-testing kit service, has announced that it will now begin telling customers about the three mutations in the breast-cancer genes BRCA1 and BRCA2 (“Authorization for Direct-to-Consumer Genetic Test on Cancer Risk,” 2018). “Being the first and only direct-to-consumer genetics company to receive FDA authorization to test for cancer risk without a prescription is …
